Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus

Redox Biology

Volumn 2, Issue 1, 2014, Pages 170-177

  Banerjee, Monisha ^a   Vats, Pushpank ^a  

^a UNIVERSITY OF LUCKNOW   (India)

Author keywords

Antioxidants; Oxidative stress; Polymorphisms; Reactive metabolites; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE TRANSFERASE; HEXOSAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; POLYOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; OXIDOREDUCTASE; SUPEROXIDE; GLUTATHIONE PEROXIDASE; NITROGEN DERIVED NON RADICAL; OXYGEN DERIVED NON RADICAL; OXYGEN RADICAL; RADICAL; REACTIVE NITROGEN SPECIES; REACTIVE THIYL RADICAL; REACTIVE TYROSYL RADICAL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL INJURY; CAT GENE; DIABETOGENESIS; DNA POLYMORPHISM; ENOS GENE; ENZYME ACTIVATION; GENETIC ASSOCIATION; GLYCEMIC LOAD; GPX 1 GENE; GPX 3 GENE; GPX 4 GENE; GPX GENE; GST GENE; HUMAN; INOS GENE; INSULIN RESISTANCE; NO GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SOD GENE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; AMINO ACID SUBSTITUTION; ENZYME ANALYSIS; ETHNIC DIFFERENCE; GENETIC ANALYSIS; GENOTYPE; INSULIN RELEASE; NONHUMAN; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HUMANS; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; SUPEROXIDES;

EID: 84892864439     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2013.12.001     Document Type: Review

References (66)

1. Moore D.J., Gregory J.M., Kumah- crystal Y.A., Simmons J.H. Mitigating micro- and macro- vascular complications of diabetes bigining in adolescence. Vasc. Health Risk Manag. 2009, 5:1015-1031.
2. http://www.idf.org.
3. Banerjee M., Saxena M. An overview and molecular genetics of type 2 diabetes mellitus. Type 2 Diabetes Mellitus: Causes, Treatment and Preventive Strategies 2012, 1-64. Nova Science Publishers Inc, New York. I. Caplis, S. Frangopoulos. (Eds.).
4. Kassab A., Piwowar A. Cell oxidant stress delivery and cell dysfunction onset in type 2 diabetes. Biochimie 2012, 94:1837-1848.
5. Johansen J.S., Harris A.K., Rychly D.J., Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol. 2005, 4:5.
6. Taniyama Y., Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertention 2003, 42:1075-1081.
7. Bonini M.G., Augusto O. Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. J. Biol. Chem. 2001, 276:9749-9754.
8. Savenkova M.L., Mueller D.M., Heinecke J.W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J. Biol. Chem. 1994, 269:20394-20400.
9. Sanchez-Gomez F.J., Espinosa-Diez C.E., Dubey M., Dikshit M., Lamas S. S-glutathionylation: relevance in diabetes and potential role as a biomarker. Biol. Chem. 2013, 394:1263-1280.
10. Woods A.A., Linton S.M., Davies M.J. Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem. J. 2003, 370:729-735.
11. Muller C.F., Laude K., Mcnally J.S., Harrison D.G. ATVB in focus: redox mechanisms in blood vessels. Arterioscler., Thromb. Vasc. Biol. 2005, 25:274-278.
12. Leopold J.A., Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1332-1340.
13. Leopold J.A., Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic. Biol. Med. 2009, 47:1673-1706.
14. Hayden M.R., Tyagi S.C. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus: Atheroscleropathy. Cardiovasc. Diabetol. 2002, 1:3.
15. Hayden M.R., Tyagi S.C. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. J. Pancreas 2002, 3:86-108.
16. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
17. Evcimen N.D., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 2007, 55:498-510.
18. Dey D., Mukherjee M., Basu D., Datta M., Roy S.S., Bandyopadhyay A., Bhattacharya S. Inhibition of insulin receptor gene expression and insulin signaling by fatty acid: interplay of PKC isoforms therein. Cell. Physiol. Biochem. 2005, 16:217-228.
19. Bloch-Damti A., Potashnik R., Gual P., Le Marchand-Brustel Y., Tanti J.F., Rudich A., Bashan N. Differential effects of IRS1 phosphorylated on Ser307 or Ser632 in the induction of insulin resistance by oxidative stress. Diabetologia 2006, 49:2463-2473.
20. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
22. Newsholme P., Haber E.P., Hirabara S.M., Rebelato E.L.O., Procopio J., Morgan D., Oliveira-Emilio H.C., Carpinelli A.R., Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol. 2007, 583:9-24.
23. Alexander S.A., Kolodgie F.D., Munn D.H., Gerrity R.G. Regulation of macrophage foam cell formation by αVβ3 integrin. Am. J. Pathol. 2004, 165:247-258.
24. Grendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916.
25. Verma S., Sagar N., Vats P., Shukla K.N., Abbas M., Banerjee M. Antioxidant enzyme levels as markers for type 2 diabetes mellitus. Int. J. Bioassays 2013, 2:685-690.
26. Fujimoto H., Taguchi J., Imai Y., Ayabe S., Hashimoto H., Kobayashi H., Ogasawara K., Aizawa T., Yamakado M., Nagai R., et al. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur. Heart J. 2008, 29:1267-1274.
27. Kakko S., Paivansalo M., Koistinen P., Kesaniemi Y.A., Kinnula V.L., Savolainen M.J. The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis 2003, 168:147-152.
28. Yamakura F., Kawasaki H. Post-translational modifications of superoxide dismutase. Biochim. Biophys. Acta (BBA) - Proteins Proteomics 2010, 1804:318-325.
29. Lee S.J., Choi M.G. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic macular edema in Korean type 2 diabetic patients. Metabolism 2006, 55:1681-1688.
30. Flekac M., Skrha J., Hilgertova J., Lacinova Z., Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med. Genet. 2008, 9:30.
31. Pacal L., Varvarovska J., Rusavy Z., Lacigova S., Stetina R., Racek J., Pomahacova R., Tanhauserova V., Kankova K. Parameters of oxidative stress, DNA damage and DNA repair in type 1 and type 2 diabetes mellitus. Arch. Physiol. Biochem. 2011, 117:222-230.
32. Yamashita K., Takahiro K., Kamezaki F., Adachi T., Tasaki H. Decreased plasma extracellular superoxide dismutase level in patients with vasospastic angina. Atherosclerosis 2007, 191:147-152.
33. Liao M., Liu Z., Bao J., Zhao Z., Hu J., Feng X., Feng R., Lu Q., Mei Z., Liu Y., et al. A proteomic study of the aortic media in human thoracic aortic dissection: implication for oxidative stress. J. Thorac. Cardiovasc. Surg. 2008, 136:65-72.
34. Juul K., Tybjaerg-Hansen A., Marklund S., Heegaard N.H., Steffensen R., Sillesen H., Jensen G., Nordestgaard B.G. Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen city heart study. Circulation 2004, 109:59-65.
35. Goth L., Lenkey A., Bigler W.N. Blood catalase deficiency and diabetes in Hungary. Diabetes Care 2001, 24:1839-1840.
36. Goth L. Catalase deficiency and type 2 diabetes. Diabetes Care 2008, 24:e93.
37. Forsberg L., Lyrenas L., de Faire U., Morgenstern R. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic. Biol. Med. 2001, 30:500-505.
38. Vitai M., Fatrai S., Rass P., Csordas M., Tarnai I. Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus. Clin. Chem. Lab. Med. 2005, 43:1346-1350.
39. Hirono A., Sasaya-Hamada F., Kanno H., Fujii H., Yoshida T., Miwa S. A novel human catalase mutation (358T-->del) causing Japanese-type acatalasemia. Blood Cells, Mol. Dis. 1995, 21:232-234.
40. Ghosh S., Janocha A.J., Aronica M.A., Swaidani S., Comhair S.A., Xu W., Zheng L., Kaveti S., Kinter M., Hazen S.L., et al. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J. Immunol. 2006, 176:5587-5597.
41. Chen H., Yu M., Li M., Zhao R., Zhu Q., Zhou W., Lu M., Lu Y., Zheng T., Jiang J., et al. Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease. Mol. Cell. Biochem. 2012, 363:85-91.
42. Dos Santos K.G., Canani L.H., Gross J.L., Tschiedel B., Souto K.E., Roisenberg I. The catalase -262C/T promoter polymorphism and diabetic complications in Caucasians with type 2 diabetes. Dis. Markers 2006, 22:355-359.
43. Tarnai I., Csordas M., Sukei E., Shemirani A.H., Kalpar M., Goth L. Effect of C111T polymorphism in exon 9 of the catalasegene on blood catalase activity in different types of diabetes mellitus. Free Radic. Res. 2007, 41:806-811.
44. Vats P., Chandra H., Banerjee M. Glutathione S-transferase and catalase gene polymorphisms with Type 2 diabetes mellitus. Dis. Mol. Med. 2013, 1:46-53.
45. Voetsch B., Jin R.C., Bierl C., Benke K.S., Kenet G., Simioni P., Ottaviano F., Damasceno B.P., Annichino-Bizacchi J.M., Handy D.E., et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke 2007, 38:41-49.
46. Thameem F., Puppala S., Arar N.H., Stern M.P., Blangero J., Duggirala R., Abboud H.E. Endothelial nitric oxide synthase (eNOS) gene polymorphisms and their association with type 2 diabetes-related traits in Mexican Americans. Diabetes Vasc. Dis. Res. 2008, 5:109-113.
47. Makuc J., Petrovic D. No association between NOS2 and NOS3 polymorphisms and diabetic nephropathy in type 2 diabetics. Cent. Eur. J. Biol. 2012, 7:404-410.
48. Cilensek I., Mankoc S., Petrovic M.G., Petrovic D. GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy. Dis. Markers 2012, 32:93-99.
49. Prabhakar R., Morokuma K., Musaev D.G. Peroxynitrite reductase activity of selenoprotein glutathione peroxidase: a computational study. Biochemistry 2006, 45:6967-6977.
50. Blankenberg S., Rupprecht H.J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K.J., et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med. 2003, 349:1605-1613.
51. Winter J.P., Gong Y., Grant P.J., Wild C.P. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron. Artery Dis. 2003, 14:149-153.
52. Ramprasath T., Murugan P.S., Prabakaran A.D., Gomathi P., Rathinavel A., Selvam G.S. Potential risk modifications of GSTT1, GSTM1 and GSTP1 (glutathione-S-transferases) variants and their association to CAD in patients with type-2 diabetes. Biochem. Biophys. Res. Commun. 2011, 407:49-53.
53. Ramprasath T., Murugan P.S., Kalaiarasan E., Gomathi P., Rathinavel A., Selvam G.S. Genetic association of Glutathione peroxidase-1 (GPx-1) and NAD(P)H:Quinone Oxidoreductase 1(NQO1) variants and their association of CAD in patients with type-2 diabetes. Mol. Cell. Biochem. 2012, 361:143-150.
54. Seiler A., Schneider M., Forster H., Roth S., Wirth E.K., Culmsee C., Plesnila N., Kremmer E., Radmark O., Wurst W., et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008, 8:237-248.
55. Loscalzo J. Membrane redox state and apoptosis: death by peroxide. Cell. Metab. 2008, 8:182-183.
56. Miller E.A., Pankow J.S., Millikan R.C., Bray M.S., Ballantyne C.M., Bell D.A., Heiss G., Li R. Glutathione- S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 2003, 171:265-272.
57. Oniki K., Umemoto Y., Nagata R., Hori M., Mihara S., Marubayashi T., Nakagawa K. Glutathione S-transferase A1 polymorphism as a risk factor for smoking-related type 2 diabetes among Japanese. Toxicol. Lett. 2008, 178:143-145.
58. Bid H.K., Konwar R., Saxena M., Chaudhari P., Agarwal C.G., Banerjee M. Association of glutathione S-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population. J. Postgrad. Med. 2010, 56:176-181.
59. Amer M.A., Ghattas M.H., Abo-Elmatty D.M., Abou-El-Ela S.H. Influence of glutathione S-transferase polymorphisms on type-2 diabetes mellitus risk. Genet. Mol. Res. 2011, 10:3722-3730.
60. Thameem F., Yang X., Permana P.A., Wolford J.K., Bogardus C., Prochazka M. Evaluation of the microsomal glutathione S-transferase 3 (MGST3) locus on 1q23 as a Type 2 diabetes susceptibility gene in Pima Indians. Human Genet. 2003, 113:353-358.
61. Casas J.P., Cavalleri G.L., Bautista L.E., Smeeth L., Humphries S.E., Hingorani A.D. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 2006, 164:921-935.
62. Hayden M.R., Tyagi S.C. In type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO and redox stress. Cardiovasc. Diabetol. 2003, 2:2.
63. Hingorani A.D. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr. Hypertens. Rep. 2003, 5:19-25.
64. Veldman B.A., Spiering W., Doevendans P.A., Vervoort G., Kroon A.A., De Leeuw P.W., Smits P. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J. Hypertens. 2002, 20:2023-2027.
65. Duplain H., Burcelin R., Sartori C., Cook S., Egli M., Lepori M., Vollenweider P., Pedrazzini T., Nicod P., Thorens B., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104:342-345.
66. Cromheeke K.M., Kockx M.M., De Meyer G.R., Bosmans J.M., Bult H., Beelaerts W.J.F., Vrints C.J., Herman A.G. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques. Cardiovasc. Res. 1999, 43:744-754.